Journal article
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation
Abstract
OBJECTIVES: We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after an acute coronary syndrome (ACS) without ST-segment elevation.
BACKGROUND: The efficacy of platelet inhibition with clopidogrel for up to one year after ACS was demonstrated in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, a randomized trial of 12,562 patients in 28 countries that was conducted between 1998 …
Authors
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S; Investigators CS
Journal
Journal of the American College of Cardiology, Vol. 45, No. 6, pp. 838–845
Publisher
Elsevier
Publication Date
3 2005
DOI
10.1016/j.jacc.2004.11.051
ISSN
0735-1097
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Acute DiseaseAgedClopidogrelCoronary DiseaseCost-Benefit AnalysisElectrocardiographyFemaleFollow-Up StudiesHumansLength of StayLife ExpectancyMaleMedicareMiddle AgedMyocardial InfarctionPatient AdmissionPlatelet Aggregation InhibitorsQuality-Adjusted Life YearsSensitivity and SpecificitySyndromeTiclopidineTimeTreatment OutcomeUnited States